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Ketogenic Diet in Refractory Childhood
Epilepsy: Starting With a Liquid
Formulation in an Outpatient Setting
Amerins Weijenberg, MD1, Margreet van Rijn, PhD2,
Petra M. C. Callenbach, PhD1 , Tom J. de Koning, MD, PhD2,3,
and Oebele F. Brouwer, MD, PhD1
Abstract
Background: Ketogenic diet in children with epilepsy has a considerable impact on daily life and is usually adopted for at least
3 months. Our aim was to evaluate whether the introduction of an all-liquid ketogenic diet in an outpatient setting is feasible, and if
an earlier assessment of its efficacy can be achieved. Methods: The authors conducted a prospective, observational study in a
consecutive group of children with refractory epilepsy aged 2 to 14 years indicated for ketogenic diet. Ketogenic diet was started
as an all-liquid formulation of the classical ketogenic diet, KetoCal 4:1 LQ, taken orally or by tube. After 6 weeks, the liquid diet
was converted into solid meals. The primary outcome parameter was time-to-response (>50% seizure reduction). Secondary
outcome parameters were time to achieve stable ketosis, the number of children showing a positive response, and the retention
rate at 26 weeks. Results: Sixteen children were included. Four of them responded well with respect to seizure frequency, the
median time-to-response was 14 days (range 7-28 days). The mean time to achieve stable ketosis was 7 days. The retention rate at
26 weeks was 50%. Of the 8 children who started this protocol orally fed, 6 completed it without requiring a nasogastric tube.
Conclusions: Introduction of ketogenic diet with a liquid formulation can be accomplished in orally fed children without major
complications. It allowed for fast and stable ketosis.
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The ketogenic diet is a high fat, very low-carbohydrate diet. It
has become one of the nonpharmacological treatment options
for children with medical refractory epilepsy, although its
mechanism of action is still unclear.1 The metabolism of a high
amount of dietary fat means that ketone bodies become the
main energy source for the whole body and brain. The efficacy
of the classical ketogenic diet for children with refractory epi-
lepsy has been strongly supported by 2 randomized controlled
trials.2,3 For children with glucose transporter type 1 deficiency
or pyruvate dehydrogenase complex deficiency, ketogenic diet
is the treatment of first choice.4
The classical ketogenic diet consists of dietary long-chain
triglycerides and is based on a ratio of 3:1 or 4:1 (fat:[carbohy-
drate þ protein]). Consequently, the amount of carbohydrate is
very restricted and the amount of protein is minimal, which
could have a negative influence on physical growth.5 A
ketogenic diet variant with medium-chain triglycerides allows
a higher intake of carbohydrates and protein, since medium-
chain triglycerides produces more ketones per kilocalorie of
energy than long-chain triglycerides. This less restrictive
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medium-chain triglycerides seems as effective as the classical
ketogenic diet.6 However, both the taste of medium-chain tri-
glycerides oil and associated gastrointestinal complaints may
compromise the intake.
In clinical practice, the mean time period for adopting the
ketogenic diet before considering its continuation/discontinua-
tion because of inefficacy is 3.5 months.7 A rapid assessment of
its efficacy is highly desirable because of the significant impact
of the ketogenic diet on the child and his or her caretakers.
Introducing an all-liquid diet requires less complicated
instructions than regular and very strict ketogenic diet meals.
The implementation of a liquid diet can be much easier for par-
ents or caretakers and ensures a more stable intake with a min-
imal risk ofmistakes. The authors hypothesized that the use of an
all-liquid formulation might contribute to an earlier and more
stable metabolic situation and level of ketosis, making earlier
assessment of efficacy possible. The authors aimed to investigate
the feasibility of introducing an all-liquid formulation of keto-
genic diet in children with refractory epilepsy and to evaluate
whether its efficacy could be assessed reliably within 6 weeks.
Materials and Methods
Patients
This prospective study was carried out in the Beatrix Children’s Hos-
pital of the University Medical Center of Groningen, the Netherlands,
between 2013 and 2016. All children, aged between 2 and 11 years
(oral feeding) or aged between 2 and 14 years (tube feeding), who
were referred for ketogenic diet treatment because of refractory epi-
lepsy and who fulfilled predefined inclusion and exclusion criteria
according to the Recommendations of the International Ketogenic
Diet Study Group7 could be included. Refractory epilepsy was defined
as inadequate seizure control despite treatment with at least 2 anti-
epileptic drugs in an optimal dose.8 Treatment with vagus nerve sti-
mulation was not considered as an exclusion criterion.
Ketogenic Diet and Procedures
Ketogenic diet was started in small groups of 2 to 4 children at the
same time. After a joint information meeting with the parents and the
ketogenic diet team, baseline investigations were performed, includ-
ing blood and urine tests, electroencephalography, electrocardiogra-
phy, renal ultrasound, bone mineral density scan, nutritional
evaluation, and evaluation of their medication. During this prephase,
individual instructions about the ketogenic diet were given to the
parents and, if possible, to their child. If there were no contraindica-
tions and parents agreed to start with an all-liquid formulation, keto-
genic diet was started without an initial fasting period in an outpatient
setting. The diet comprised an all-liquid formulation (KetoCal 4:1 LQ)
taken orally or by tube with a 10-day, stepwise conversion into a
classical liquid ketogenic diet, with a ratio 4:1 of fat:(carbohydrate
þ protein). A slower introduction was allowed on an individual basis.
KetoCal 4:1 LQ could be mixed with carbohydrate-free flavors. All
children who could tolerate oral feedings were allowed to have a low-
carbohydrate snack, like a piece of cucumber, once or twice a day.
Levels of ketosis and glucose were measured in capillary blood sam-
ples twice a day (morning and evening) during the first 2 weeks and
thereafter once a week and when indicated.
After the introductory phase of 6 weeks, the classical, liquid keto-
genic diet was converted into a diet consisting of meals combined with
both long-chain triglycerides (KetoCal 4:1 LQ and/or oral dietary
products) and medium-chain triglycerides, allowing more protein and
carbohydrates to be consumed. The content of the diet was adjusted to
calculated percentages of total energy, initially aiming for a distribu-
tion of medium-chain triglycerides 43%, long-chain triglycerides
35%, protein 12%, and carbohydrate 10%. Fine-tuning of the diet was
based on tolerability, level of ketosis, growth, and individual needs
and preferences. During this transition phase, ketosis was measured
daily in the evening, until it had again stabilized. Children were seen
in the outpatient clinic every 2 weeks during the introductory phase
and then regularly until 52 weeks after the start of the all-liquid keto-
genic diet.
The study was performed according to the guidelines of the Uni-
versity Medical Center Groningen’s medical ethics committee. Since
ketogenic diet is part of the regular treatment options for children
with pharmacologically resistant epilepsy, the ethics committee did
not need to make a formal assessment of this observational study.
Outcomes
Parents and children were asked to keep a diary, including a 4-week
baseline period, before the start of the ketogenic diet. The diary
included items like seizure type and frequency, use of emergency
medication, levels of ketosis and blood glucose, adverse events with
special attention for constipation and vomiting, and other individual
details when applicable. Changes in antiepileptic drugs during the first
6 weeks were allowed only if they were considered really necessary
and these had to be recorded in the diary too.
The primary outcome parameter was time-to-response, defined as
time to the first day of a period of at least 7 consecutive days with
>50% seizure reduction compared to the seizure frequency before the
start of ketogenic diet. Secondary outcome parameters were time to
achieve stable ketosis (defined as 2.5 mmol/L in blood for at least
2 days); the number of children showing a positive response (respon-
der rate) at 6, 12, and 26 weeks; the retention rate at 26 weeks; and the
reasons for discontinuation of ketogenic diet.
Results
Patients
Between April 2013 and January 2016, a liquid ketogenic diet
was initiated in 16 children. Their clinical characteristics are
shown in Table 1. In 10 of 16 children, the seizure frequency
was uncountable before the start of ketogenic diet or seizures
could not be adequately registered by the parents (difficult to
interpret, inconsistent presentation). All children except 1 had
multiple seizure types.
Efficacy and Tolerability
Table 2 shows the primary and secondary outcome parameters
together with the main aspects concerning tolerability. Only 4
of the 16 children responded well in relation to their seizure
frequency, with all of them achieving a response within 4
weeks after the start of the ketogenic diet (Table 2). There were
no further responders after 6 weeks. Follow-up time was at
least 1 year. The mean time taken to achieve stable ketosis was
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7 days (15/16 children). One child never reached the desired
level of ketosis (2.5 mmol/L). Not only the 4 responders
stayed on the diet after the 6-week introductory phase; 8 chil-
dren did so for at least 26 weeks (ie, the retention rate at
26 weeks was 50%, both in orally fed and tube-fed children).
Apart from reduction in seizure frequency, additional reasons
for continuing ketogenic diet, as reported by the parents in their
diaries, were changes in seizure type (shorter and/or less severe
seizures); less need for emergency medication; and improve-
ment of alertness, cognitive functioning (eg, starting to speak
words again, walking again), and/or physical well-being (eg,
being able to go to school every day).
In the 8 children who stopped ketogenic diet after 6 weeks,
the reasons for discontinuing the diet were inefficacy and/or
lack of other benefits, which did not outweigh the burden of the
diet. There were no changes to their antiepileptic drug regimens
during the first 6 weeks.
Generally, the ketogenic diet was well tolerated. Constipa-
tion, the most common adverse event, could be easily con-
trolled by laxatives. Two children needed a high enema





















1/M 1; 2 1; 11 3 Epileptic
spasms
West syndrome Unknown Uncountableb Severe
2/M 0; 1 4; 8 3 Focal motor Multifocal Unknownc 30 Severe
3/F 0; 3 3; 2 3 Focal motor Focal Unknown 30 Moderate





5/M 6; 1 11; 7 3 Focal motor Focal KCNT1-mutation 50 Moderate





7/F 0; 1 6; 6 2 Generalized
tonic-clonic
Multifocal Unknown Uncountable Moderate
8/M 0; 4 7; 1 3 Focal
nonmotor




9/M 2; 0 7; 7 4 Generalized
tonic





10/M 1; 0 6; 1 1 Generalized
tonic-clonic
Multifocal Unknown Uncountable Severe




12/M 7; 9 9; 0 4 Generalized
tonic




13/M 10; 9 14; 11 3 Focal motor Multifocal Cri du Chat syndrome
(5p deletion and 4q
deletion)
65 Severe
14/F 1; 8 2; 5 2 Generalized
atonic
Lennox Gastaut Unknown Uncountable Severe









Abbreviations: AEDs, antiepileptic drugs; EEG, electroencephalography; HSV, herpes simplex virus; KD, ketogenic diet; NA, not applicable; NMDA, N-methyl-D-
aspartate.
aNumber of AEDs and seizures at KD initiation, respectively.
bUncountable ¼ seizure frequency was too high to count or seizures could not be accurately registered (too difficult to interpret, unreliable presentation).
cBrother died of Mitochondrial DNA depletion syndrome (mtDNA) depletion syndrome.
dTapering off of 1 of 2 AEDs started before the introduction of KD and was withdrawn 4 weeks after starting KD.
eUncertain whether attacks were of epileptic origin.
fWithout typical EEG correlation.
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during the introductory phase. None of the children experi-
enced an increase in vomiting or other gastrointestinal prob-
lems. Introducing the ketogenic diet in an outpatient setting
was found to be safe; 2 children had 1 or 2 episodes with
vomiting, most likely due to high ketosis (maximums of 5.6
and 7.6 mmol/L) combined with hypoglycemia (1.4 and
2.0 mmol/L, respectively) in the first week, for which they
were seen in hospital and could easily be controlled with extra
carbohydrates. It appeared that in one of these children, the
ketogenic diet had been introduced too rapidly by the mother
(within 2 days) instead of using the stepwise instructions for the
ketogenic diet. One child, who was electively hospitalized
before the start of ketogenic diet for social reasons, had unex-
plained high ketosis (maximum 6.6 mmol/L) in the first week
without further symptoms and with normal blood glucose,
which could be corrected with extra carbohydrates.
Ketogenic Diet: All-Liquid Introduction and Transition
to Meals
Half of the children were already being tube-fed before keto-
genic diet was initiated. For these children and their parents
initiating ketogenic diet with an all-liquid formulation was
relatively simple. The remaining 8 children were also started
with a complete liquid ketogenic diet although they were
allowed to replace the liquid formula by an equivalent
amount of KetoCal 4:1 LQ as a muffin or pancake based
on the KetoCal 4:1 powder, if liquid intake only became
problematic. This was only done incidentally. In addition,
they were also allowed to have a low-carbohydrate chewable
snack, such as a piece of cucumber. Two children received a
nasogastric tube temporarily during the first weeks of the
introductory phase: one child, known with behavioral prob-
lems, because of difficult intake of the KetoCal 4:1 LQ, the
other because of insufficient dietary intake before initiating
the ketogenic diet. The latter received a percutaneous endo-
scopic gastrostomy (tube) after discontinuation of ketogenic
diet. During the introductory phase, all the children main-
tained a stable bodyweight. After the conversion to solid
meals, 5 of the 6 children without a tube continued using
KetoCal 4:1 LQ in their diet for at least another 6 weeks,
in combination with oral food preparations and medium-
chain triglycerides. For the tube-fed children, the ketogenic
diet was adapted by adding medium-chain triglycerides and
increasing the amount of protein given. The characteristics of
the ketogenic diet during the introductory phase (classical
ketogenic diet at 4 weeks) and after the transition to meals
(variant with medium-chain triglycerides at 12 weeks) for
each patient are shown in Table 3. In 2 children who were
totally tube-fed, the classical ketogenic diet was not adapted
after 6 weeks because of other severe health problems.
Discussion
Our study shows that introduction of ketogenic diet with a
liquid formulation in an outpatient setting is feasible and con-
tributes to achieving a rapid and stable ketosis. Only 1 child did
not achieve stable ketosis, which was probably due to noncom-
pliance. In all the children who had a >50% decrease of seizure
frequency, time-to-response was less than 4 weeks. Our study
therefore supports the idea that it is possible to evaluate the
efficacy of this type of ketogenic diet within 6 weeks. This is in
line with others who have concluded that most children who

















1 Yes 28 8 2.6-4.0 49 Yes No No No
2 No NA 2 2.1-5.9 14 No No Yes No
3 Yes 15 7 2.2-5.4 >65c Yes Yes Yes No
4 No NA 7 2.7-4.9 7 No No Yes No
5 No NA 7 2.7-5.9 97 Yes Yes No No
6 No NA 13 2.7-5.9 >165c Yes Yes No No
7 No NA 1 3.5-5.3 11 No No Yes Beforehand
8 Yes 7 6 3.3-4.6 >203c Yes Yes Yes No
9 No NA NA 0.7-1.9 17 No No Yes No
10 No NA 2 2.4-5.3 15 No No Yes Yes
11 No NA 6 2.4-5.4 19 No No No No
12 No NA 20 1.1-5.5 41 Yes No No No
13 No NA 11 2.7-5.5 9 No No No No
14 No NA 5 2.8-5.2 26 Yes No Yes No
15 Yes 14 5 2.6-5.0 >141c Yes Yes No Yes
16 No NA 4 1.9-3.6 12 No No Yes No
Abbreviations: KD, ketogenic diet; NA, not applicable.
aResponse was defined as >50% seizure reduction.
bLevel of ketosis week 3 to 6: 10-90 percentiles.
cStill continuing KD in April 2017.
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show a positive effect on ketogenic diet have a seizure reduc-
tion within the first 2 weeks and that it is reasonable to dis-
continue the ketogenic diet if it did not result in a seizure
reduction after 8 weeks.9 Although individual choices exist,
most parents are counselled to continue the ketogenic diet, even
if apparently ineffective, for at least 3 months as recommended
by the International Ketogenic Diet Study Group.7 More stud-
ies are needed to support that efficacy of the ketogenic diet with
solid foods can be evaluated within 6 weeks.
Introducing the ketogenic diet with this all-liquid formula-
tion, KetoCal 4:1 LQ, was simple, minimizing potential dietary
errors and with a mean time period of less than 7 days to
achieve stable ketosis. In particular, for children who were
already tube-fed and for those in an intensive care setting, a
liquid diet can be beneficial.10,11 Also for children who are
reluctant to eat ketogenic diet, a liquid ketogenic diet using a
formula-based powder is a good alternative.12 In general, it was
well accepted by parents and children. None of the parents or
children decided to discontinue or change the diet because of
the all-liquid formulation. The intention was to start and stay
all-liquid for 6 weeks, but incidentally children were allowed to
eat a muffin or pancake based on the Ketocal 4:1 powder,
instead of the equivalent amount of KetoCal 4:1 LQ. This
happened only sporadically and the risk for dietary errors by
allowing this muffin was negligibly small. The level of ketosis
in these children remained stable. During the transition to keto-
genic meals after 6 weeks, the ketosis in the children became
less stable and it took some time to personalize the diet with
medium-chain triglycerides and reach stable ketosis again. This
did not cause an increase of seizure frequency or a decrease in
well-being during this period.
An all-liquid, ready-to-use ketogenic diet formulation
including medium-chain triglycerides is not yet available
commercially. This makes the transition from the all-liquid
phase to solid meals more complicated if a diet with medium-
chain triglycerides and more protein is preferred. In total, the
dietician’s time investment was about the same as that for
children who immediately started treatment with a variant
of the ketogenic diet with meals, but the transition for children
and parents/caretakers was split into easier to manage steps:
first adjusting to following a strict diet and monitoring blood
values, and later on learning to prepare solid meals with the
ingredients permitted.
The responder rate in our study was 25%. This included 1
child with a glucose transporter type 1 deficiency, which is
generally known to respond well to ketogenic diet. Our
responder rate is lower than the response rate of 38% to
50% reported in 2 randomized control trials.2,3 The most
likely explanation for this is the severity of the children’s
epilepsy in our study, which seems obvious when looking at
their seizure frequencies. In 10 of 16 children, the seizure
frequency could even not be determined because the seizures
were uncountable, many of the seizures were too difficult to
interpret for parents, or seizures went unnoticed. A limitation
of our study was the absence of a control group on regular
ketogenic diet for comparing responder rate.
The retention rate at 26 weeks of 50% suggests that also
other aspects are considered important in the decision to con-
tinue ketogenic diet. Some of those are quite subjective, in
particular those regarding the child’s well-being, and were not
formally tested. Retention rate has been suggested as a more
useful outcome parameter than the >50% reduction of seizure













at 12 Weeks (%)
1 Yes 12.0 0.13 1.5 1.5 6.3 0a
2 Yes 16.4 1.00 1.5 1.5 6.6 30.3
3 Yes 14.2 þ1.13 1.8 2.2 6.0 11.8
4 Yes 13.8 þ0.50 1.6 NA NA NA
5 No 37.8 0.35 1.0 1.4 6.1 31.9
6 Yes 16.0 1.41 1.3 1.9 5.8 0b
7 Noc 18.4 þ0.03 1.3 2.1 5.6 47.1
8 No 23.9 0.19 1.5 1.9 7.2 43.6
9 No 26.5 þ0.24 1.1 1.7 6.7 33.0
10 Noc 21.0 0.81 1.5 1.8 6.4 26.7
11 No 16.9 0.03 1.5 1.9 7.0 41.5
12 Yes 26.8 þ0.21 1.4 1.4 6.5 0a
13 Yes 39.7 1.21 1.0 NA NA NA
14 No 15.5 þ1.81 1.4 2 5.4 26.1
15 No 22.2 þ0.76 1.5 2.5 5.2 37.9
16 Yes 16.5 þ1.71 0.9 1.4 3.9 0b
Abbreviations: BMI, body mass index; KD, ketogenic diet; kg, kilogram; kgbw, kilogram bodyweight; MCT, medium-chain triglyceride; NA, not applicable; SD,
standard deviation (based on age).
aClassical KD.
bVery low energy intake.
cPatients 7 and 10 needed a tube during the introduction phase.
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frequency, which is especially true for children with many or
even uncountable seizures.13–15 Retention rate combines
efficacy and tolerability, but also perceived improvement in
activities of daily living and quality of life. It also reflects the
impact of a diet on the patient and family’s daily life.
Constipation was the most common adverse event of the
ketogenic diet, occurring in 9 of 16 children; it is a well-
known complication of the diet. The authors did not observe
any other gastrointestinal symptoms such as vomiting and diar-
rhea.16 Constipation was mostly solved by adding laxatives.
The 2 children who needed enemas during the introductory
phase had already dealt with persistent constipation before the
ketogenic diet introduction. All parents experienced being able
to perform the introduction at home as an advantage of our
treatment protocol. More importantly, the introduction at home
proved to be safe. Initiating ketogenic diet in an outpatient
setting is becoming more common and is also standard care
in another ketogenic diet center in the Netherlands.17
One of the long-term concerns of the classical ketogenic diet
is its negative effect on physical growth due to its limited
protein content.5 The ketogenic diet variant with medium-
chain triglycerides has the advantage of allowing a higher
amount of protein and carbohydrates compared to the classical
ketogenic diet (Table 3). Still, no significant differences in
growth were found between the classical and medium-chain
triglycerides diet groups after 12 months, despite the signifi-
cantly higher protein intake in the medium-chain triglycerides
diet.5 In our ketogenic diet with medium-chain triglycerides,
we prescribed even more protein than Neal et al5—with a mean
content of 1.86 g/kg compared to 1.67 g/kg. In our study, the
growth rates were within normal limits for the children who
were on the ketogenic diet for more than 6 months (n ¼ 8) or
more than a year (n ¼ 5), except for 1 child whose growth was
stable at 1 standard deviation below his original growth curve.
Conclusion
Our results suggest that introduction of ketogenic diet with a
liquid formulation is feasible, with good tolerability and accep-
tance, and the diet can be safely introduced in an outpatient
setting. It can be easily applied in tube-fed children but is also a
good alternative for insecure parents or in difficult social situa-
tions. The mean time to achieving stable ketosis was within
7 days, with a median time-to-response of 2 weeks. Early stable
ketosis and a short time period to response made it possible to
assess the ketogenic diet’s efficacy within 6 weeks, which is an
advantage as well. Although the positive response rate was low
(4/16), the parents of another 4 children were satisfied with the
diet because it led to less severe seizures or improved well-
being, which resulted in a retention rate of 50% after 6 months.
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